Clinical trials
HIV 2 Infection clinical trials
Below are recruiting hiv 2 infection clinical trials, each written for real people, not researchers. We’re tracking 143 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07643948Recruiting
How HIV Treatment Changes Affect Drug Resistance
This study follows people with HIV whose virus is well-controlled on current medications to understand how switching to a different HIV drug regimen affects the virus's ability to resist those drugs. The goal is to help doctors choose the safest treatment switches.
Hong Kong, Hong KongAges 18 years+ - NCT05602376Recruiting
HIV messages to help men get tested and stay in care
This study tests whether special “U=U” style messages can improve how men move from HIV testing to starting treatment and continuing care. You may be asked to receive guidance and information meant to help you stay engaged in HIV treatment.
East London, Eastern CapeAges 15 years+ - NCT05848570Recruiting
Digital program for reducing HIV risk in SGM youth
This trial tests a digital health program (available with limited in-person contact) to help SGM young people reduce their risk of HIV. You may be a good fit if you’re in the right age range and have had certain types of sex in the last 6 months.
Chicago, IllinoisAges 13–34 - NCT05947539Enrolling by invitation
Helping Ugandan young women stay engaged in HIV care
This study tests a couples-focused program to help HIV-positive adolescent girls and young women stay connected to HIV clinic visits and medicines. It may help if you’re currently not well engaged in HIV care or you’ve faced partner violence or controlling behavior.
KampalaAges 15 years+ - NCT05077527RecruitingPhase 1
CAR-T treatment for HIV and aggressive B-cell lymphoma
This trial studies a lab-made immune cell treatment (CAR-T) for adults who have HIV and aggressive B-cell non-Hodgkin lymphoma that has come back or did not respond to prior treatment. It aims to see if the treatment can control the lymphoma safely in this specific group.
Duarte, CaliforniaAges 18 years+ - NCT06310551RecruitingPhase 1
Long-acting HIV prevention study for healthy adults
This study tests a new long-acting medicine that may help prevent HIV. It is given as an injection, and the study checks how safe it is and how it works in healthy volunteers.
Lenexa, KansasAges 18–55 - NCT06684613Recruiting
PrEP decision-making counseling for women in sexual health clinics
This study tests a counseling program to help women decide whether to use PrEP (a daily pill that prevents HIV). It aims to make PrEP choices easier and more informed in sexual and reproductive health clinics.
New Haven, ConnecticutAges 18 years+ - NCT04052022Recruiting
Study of TB flare-ups in people without HIV
This study looks at why some people with tuberculosis (TB) get worse or develop new inflammation after they initially start improving on treatment—called a “paradoxical reaction.” It collects blood and tissue samples to better understand these flare-ups and guide future care.
Bethesda, MarylandAges 18–99 - NCT04499053RecruitingPhase 2
Durvalumab and tremelimumab with chemotherapy for advanced lung cancer in HIV
This trial tests a combination of immune therapy drugs (durvalumab and tremelimumab) given with chemotherapy in people with stage IV non-small cell lung cancer who also have HIV. It may help shrink or control cancer by boosting the immune response while keeping HIV well controlled.
Washington D.C., District of ColumbiaAges 18 years+ - NCT07525544RecruitingPhase 1
Safety Study of VH4770359 in Healthy Adults
This is an early-stage safety study testing a new investigational drug (VH4770359) in healthy volunteers. Researchers want to understand how the body processes the drug and ensure it is safe and well-tolerated.
Baltimore, MarylandAges 18–55 - NCT05418868RecruitingPhase 1
Long-acting cabotegravir injection safety in healthy adults
This Phase 1 study tests how the body handles a long-acting (slow-release) cabotegravir injection combined with a drug called hyaluronidase. It also checks safety and side effects in healthy adults to help future HIV-prevention or treatment plans.
Orlando, FloridaAges 18–55 - NCT05515770RecruitingPhase 3
Injectable PrEP shot for HIV prevention in higher-risk adults
This Phase 3 study tests whether an injectable HIV prevention medicine (cabotegravir) given before exposure can help prevent HIV in people at higher risk. You may join if you are HIV-negative and meet specific sexual health, medication, and health-testing requirements.
Rio de JaneiroAges 18–30 - NCT05633056Recruiting
Testing TB medicines for people with drug-resistant TB and HIV
This trial studies a treatment plan for people who have both drug-resistant tuberculosis (TB) and HIV. It focuses on starting a specific TB medication (bedaquiline) and, if needed, HIV treatment soon after enrollment to see what approach works best.
Durban, KwaZulu-NatalAges 18 years+ - NCT05663502Recruiting
Donate blood and tissue samples for HIV-related cancer research
This study collects blood and tissue samples to help researchers learn more about cancers related to HIV/AIDS. You may be able to join if you’re 18+ and have HIV and a cancer diagnosis, or (if HIV-negative) a certain cancer that is closely linked to AIDS-related cancers.
La Jolla, CaliforniaAges 18 years+ - NCT05674656RecruitingPhase 1/Phase 2
Testing dolutegravir and rilpivirine in HIV-positive children
This study checks how safe and well two HIV medicines work in children ages 6 to under 12. It also measures drug levels in the body to guide dosing and watch for side effects.
Long Beach, CaliforniaAges 6–12 - NCT05789901Recruiting
Using a Facebook chatbot to share health information
This study tests whether a Facebook Messenger chatbot can provide helpful health information for different conditions. You may help researchers check if people can use the chatbot and understand the information.
Montreal, QuebecAges 14 years+ - NCT05842161Recruiting
Help quitting smoking for people with HIV and TB care
This study supports quitting smoking while you are receiving HIV and/or TB care. It aims to improve engagement in care and smoking cessation for people who smoke daily.
RondeboschAges 18 years+ - NCT06139224Recruiting
Gut Bacteria and Inflammation in HIV and Heavy Drinking
This study looks at how gut bacteria and inflammation interact in people with both HIV and heavy alcohol use. It aims to find new ways to improve health by understanding these connections.
Chicago, IllinoisAges 45–75 - NCT06216600Recruiting
Women's strength and resilience program for HIV and substance use
This study tests a program for women living with HIV who also struggle with substance use or heavy drinking. It combines exercise and support to help build strength and resilience. You may qualify if you've missed some HIV medications, have a detectable viral load, and have experienced violence.
San Diego, CaliforniaAges 18 years+ - NCT06226155Recruiting
HIV prevention support for pregnant women in Zimbabwe
This study in Zimbabwe tests a program to help pregnant women start and stay on PrEP (medication that prevents HIV). It aims to make PrEP easier to use during pregnancy for women who are at risk of HIV.
HarareAges 15–55 - NCT06281834RecruitingPhase 1
Dolutegravir levels with TB prevention in children
This study tests how dolutegravir (an HIV medicine) works in children when taken with weekly rifapentine and isoniazid (medicines to prevent tuberculosis). It may help find the right dose for kids who have HIV and are at risk for TB.
Ibadan, Oyo StateAges 4 weeks–11 years - NCT06370780Recruiting
Smartphone app to help with HIV viral suppression
This study uses a smartphone app to help people with HIV who have trouble staying virally suppressed stay healthy. It’s for those who are not currently suppressed, not in care, or at risk of becoming unsuppressed.
Los Angeles, CaliforniaAges 18 years+ - NCT06619288Recruiting
HIV treatment study comparing B/F/TAF to older drugs
This study tests a newer HIV medication, B/F/TAF, as a first-line treatment. It compares B/F/TAF with older combinations (TDF+3TC+EFV or DTG/3TC) to see how well it works for people who have never taken HIV meds.
Nantong, JiangsuAges 18 years+ - NCT06665646RecruitingPhase 1
HIV vaccine booster study for previous trial participants
This study tests a booster vaccine for HIV in people who were part of an earlier HIV vaccine trial. The goal is to see if it's safe and helps the immune system fight HIV better.
San Francisco, CaliforniaAges 18–60
Hear when a new HIV 2 Infection trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for hiv 2 infection?
- Yes. Clin2 currently lists 143 recruiting hiv 2 infection studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a hiv 2 infection trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a hiv 2 infection trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.